KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Receivables (2016 - 2025)

Sarepta Therapeutics has reported Change in Receivables over the past 15 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Change in Receivables at $2.5 million for Q4 2025, down 98.51% from a year ago — trailing twelve months through Dec 2025 was -$203.8 million (down 201.04% YoY), and the annual figure for FY2025 was -$203.8 million, down 201.04%.
  • Change in Receivables for Q4 2025 was $2.5 million at Sarepta Therapeutics, up from -$131.6 million in the prior quarter.
  • Over the last five years, Change in Receivables for SRPT hit a ceiling of $167.5 million in Q4 2024 and a floor of -$132.1 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was $13.0 million (2022), compared with a mean of $14.8 million.
  • Biggest five-year swings in Change in Receivables: soared 3598.81% in 2023 and later plummeted 602.2% in 2025.
  • Sarepta Therapeutics' Change in Receivables stood at $3.2 million in 2021, then soared by 309.58% to $13.1 million in 2022, then soared by 521.02% to $81.5 million in 2023, then surged by 105.55% to $167.5 million in 2024, then tumbled by 98.51% to $2.5 million in 2025.
  • The last three reported values for Change in Receivables were $2.5 million (Q4 2025), -$131.6 million (Q3 2025), and -$132.1 million (Q2 2025) per Business Quant data.